首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   15篇
  免费   3篇
  国内免费   1篇
基础医学   2篇
临床医学   6篇
内科学   4篇
神经病学   3篇
药学   2篇
肿瘤学   2篇
  2023年   1篇
  2022年   2篇
  2021年   3篇
  2020年   1篇
  2018年   2篇
  2016年   3篇
  2015年   3篇
  2014年   1篇
  2013年   1篇
  2006年   1篇
  2004年   1篇
排序方式: 共有19条查询结果,搜索用时 7 毫秒
11.
12.
A multiplex PCR was developed for simultaneous detection of the cytolethal distending toxin (cdt) genes of Campylobacter jejuni. Three primer pairs targeting each one of the cdtA, cdtB and cdtC genes were designed and combined in the same PCR reaction. The assay was evaluated with 100 C. jejuni strains recovered from humans and animals and it was found to be rapid and specific. Two isolates presented several deletions affecting both cdtA and cdtB genes. High prevalence (98%) of the three cdt genes was found among isolates of different geographic origins.  相似文献   
13.
The dynamic recrystallization behavior of ultra-high strength boron-microalloyed steels optionally alloyed with niobium and molybdenum is analyzed in this paper. Multipass torsion tests were performed to simulate plate rolling conditions followed by direct quenching. The influence of alloy composition on the transformed microstructure was evaluated by means of EBSD, thereby characterizing the morphology of the austenite grain morphology after roughing and finishing passes. The results indicated that for Nb-microalloyed steel, partial dynamic recrystallization occurred and resulted in local clusters of fine-sized equiaxed grains dispersed within the pancaked austenitic structure. A recrystallized austenite fraction appeared and transformed into softer phase constituents after direct quenching. The addition of Mo was shown to be an effective means of suppressing dynamic recrystallization. This effect of molybdenum in addition to its established hardenability effects hence safeguards the formation of fully martensitic microstructures, particularly in direct quenching processes. Additionally, the circumstances initiating dynamic recrystallization were studied in more detail, and the interference of the various alloying elements with the observed phenomena and the potential consequences of dynamic recrystallization before quenching are discussed.  相似文献   
14.
15.

Background

Restless legs syndrome (RLS) is a neurological disorder characterised by bothersome symptoms associated with impaired quality of life and sleep hygiene. Rotigotine is a novel therapeutic alternative, although few studies have been published in patients on haemodialysis (HD) with RLS treated with rotigotine.

Objectives

1.- To establish the prevalence of RLS in our HD unit. 2.- To evaluate the efficacy and safety profile of rotigotine and its effect on symptoms, quality of life and sleep hygiene in our HD population with RLS.

Material and methods

A single-centre, 12-week prospective study. Two stages (6 weeks): stage 1 (no treatment) and stage 2 (rotigotine). We analysed: 1.- Demographic data, biochemistry data, HD suitability parameters and RLS medical treatment data. 2.- Lower extremity symptoms questionnaire (QS). 3.- RLS severity symptoms scale (SRLSS). 4.- RLS Quality of life: John Hopkins RLS-QoL (JH-QoL). 5.- Sleep hygiene: SCOPA Scale.

Results

We included 66 HD patients, 14 with RLS; 44.4% male, 70.2 ± 9.9 years and 111.1 ± 160.8 months on HD. And 22.9% RLS. Exclusively in stage 2, a significant improvement for QS (10 ± 2.4 vs. 5.7 ± 1.0), SRLSS (21 ± 4 vs. 5.7 ± 4.6), JH-QoL (22.1 ± 4.4 vs. 4.3 ± 4.0) and SCOPA (16 ± 5.3 vs. 6.7 ± 1.9) were observed. A 77.7 and 11.1%, showed partial (> 20%) and complete (> 80%) remission, respectively, while 55.5% achieved «zero» symptoms. Only one patient had gastrointestinal intolerance and none experienced augmentation effect. No changes in biochemical data, suitability for dialysis or medical treatment were found. The inter-group analysis showed a significant improvement in relation to QS, SRLSS, JH-QoL and SCOPA in stage 2.

Conclusions

RLS showed a considerable prevalence in our HD unit. Rotigotine improved clinical symptoms, quality of life and sleep hygiene in RLS patients on HD and was found to be a safe drug with minimal side effects and total therapeutic compliance. Nevertheless, future studies should be performed to confirm the benefits of rotigotine in RLS patients on haemodialysis.  相似文献   
16.
Febuxostat is a non-purine, selective inhibitor of both isoforms of xanthine oxido-reductase (XOR), and a major alternative to the scarce number of urate-lowering medications available in the last decades. Its inhibition of XOR is more potent than allopurinol in a mg to mg comparison, what is associated to achievement of serum urate target more frequently than allopurinol at doses tested in clinical trials, especially in patients with the highest baseline serum urate levels. Its pharmacokinetics is not greatly dependent on renal clearance, contrary to allopurinol, what may be an advantage in patients with chronic kidney disease. Several trials are further evaluating both the cardiovascular safety of febuxostat and its possible beneficial effect on renal function preservation. Still scarce, but clinically interesting, evidence on its use in transplant patients has been recently released.  相似文献   
17.
18.
The influence of toll-like receptor 4 on neurogenesis and inflammation has been scarcely explored so far by using neuroimaging techniques. For this purpose, we performed magnetic resonance imaging and positron emission tomography with 3′-deoxy-3′-[18F]fluorothymidine and [11C]PK11195 at 2, 7, and 14 days following cerebral ischemia in TLR4+/+ and TLR4−/− mice. MRI showed similar infarction volumes in both groups. Despite this, positron emission tomography with 3′-deoxy-3′-[18F]fluorothymidine and [11C]PK11195 evidenced an increase of neurogenesis and a decrease of inflammation in TLR4−/− mice after ischemia. These results evidence the versatility of neuroimaging techniques to monitor the role of toll-like receptor 4 after cerebral ischemia.  相似文献   
19.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号